Readout LOUD podcast: FDA AI experiment, Novo trails in obesity

Adam Feuerstein is a senior author and biotech columnist, reporting on the crossroads of drug improvement, enterprise, Wall Road, and biotechnology. He’s additionally a co-host of the weekly biotech podcast The Readout Loud and writer of the publication Adam’s Biotech Scorecard. You’ll be able to attain Adam on Sign at stataf.54.

Allison DeAngelis is the East Coast biotech and enterprise capital reporter at STAT, reporting the place scientific concepts and cash meet. She can be co-host of the weekly biotech podcast, The Readout Loud. You’ll be able to attain Allison on Sign at AllisonDeAngelis.01.

On this week’s episode of “The Readout LOUD”: The Meals and Drug Administration’s AI journey, a deep look inside Novo Nordisk’s weight problems stumble, and at last, one other large M&A deal in biotech.

The FDA has rolled out an inside AI software referred to as Elsa that, in contrast to its namesake Disney character, can’t appear to let go of errors. Our colleague Brittany Trang joins to clarify. And it’s all the time a enjoyable podcast after we can focus on a biotech acquisition. This week, we’ll chat about Sanofi’s $9 billion provide for Blueprint Medicines.

However first, Novo Nordisk was as soon as the chief within the weight problems drug race. Right this moment, it trails Eli Lilly. Our co-host Elaine Chen has a brand new story printed this week that examines the explanations behind Novo’s fall and what it’s doing to catch up. You’ll hear all about it.

Make sure to join “The Readout LOUD” on Apple Podcasts, Spotify, or wherever you get your podcasts.